Skip to main content

Find a trial

Find a trial

Trial status
Trial Phase
Trial type
10 clinical trials grid list download
  • Title Organ Phase Statut Major inclusion criteria Contact
  • 1367.1 An open label, Phase Ia/Ib dose finding study with BI 894999 orally administered once a day in patients with advanced malignancies, with repeated administration in patients with clinical benefit Multiple phase 1 Closed any line, RECIST 1.1 Ahmad Hussein Awada
  • AMC303-01 A safety, tolerability and pharmacokinetic dose escalation expansion, Phase I/Ib study of AMC303 as monotherapy in patients with advanced or metastatic, malignant solid tumour of epithelial origin Multiple phase 1/1b Closed any line, RECIST 1.1 Philippe Aftimos
  • EORTC 1658 Qualification of imaging methods to assess cancer drug induced interstitial lung disease (ImageILD) Lung Closed any line / Lung metastasis Konstantinos Stathopoulos
  • I7W-MC-JQBA A Phase 1 Study of LY3127804 as Monotherapy and in Combination with Ramucirumab in Patients with Advanced Solid Tumors Multiple phase 1 Closed RECIST 1.1, after standard trerapy Ahmad Hussein Awada
  • IJB_2728 Improving emotion regulation for patients with metastatic cancer: A pilot study assessing the impact of a multi-component psychological group intervention Solid tumors Open Metastatic, any tumors
  • Intervention destinée aux parents L'enfant face au cancer d'un parent: une étude randomisée évaluant l'efficacité d'une intervention psychologique destinée à soutenir la parentalité Solid tumors Open Be a parent or close relative of a child between the ages of 3 and 18 confronted with parental cancer, any tumors
  • IPAX-1 A multi-centre, open-label, single-arm, dose-finding phase I/II study to evaluate safety, tolerability, dosing schedule, and preliminary efficacy of carrier-added 4-L-[131I]iodo-phenylalanine (131I-IPA), administered as single or repetitive injections in patients with recurrent glioblastoma multiforme (GBM), concomitantly to 2nd line external radiation therapy (XRT) - IPAX-1 Liver phase 1/2 Open *Previously confirmed histological diagnosis of glioblastoma, with current clinical or imaging evidence for recurrence *Interval since end of 1st line XRT superior or equal to 6 months
    *Amino acid-based molecular imaging indicating pathologically increase
    Patrick Flamen
  • OX2016-203-01 An open-label, dose-escalation, phase I study to assess the safety, pharmacokinetics and pharmacodynamics of AsiDNA, a DNA repair inhibitor administered intravenously in patients with advanced solid tumors Multiple phase 1 Closed Any line/RECIST v1.1/Eligible for platinium salt chemotherapy Nuria Kotecki
  • Sevrage Tabagique Impact of an emotion and craving regulation intervention on smoking cessation and maintenance among oncology patients : a randomized study Solid tumors Open Smoker of quit smoking within the last 6 months, any tumors
  • SYD985.004 A two-part phase I study with the antibody-drug conjugate SYD985 in combination with niraparib to evaluate safety, pharmacokinetics and efficacy in patients with HER2-expressing locally advanced or metastatic solid tumours Multiple phase 1 Closed RECIST v1.1 Philippe Aftimos